Cerus Stock Today
| CERS Stock | USD 1.45 0.06 4.32% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Cerus is selling for under 1.45 as of the 15th of March 2025; that is 4.32% increase since the beginning of the trading day. The stock's lowest day price was 1.39. Cerus has over 56 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 15th of December 2024 and ending today, the 15th of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 30th of January 1997 | Category Healthcare | Classification Health Care |
Cerus Corporation operates as a biomedical products company. The company was incorporated in 1991 and is headquartered in Concord, California. Cerus Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 631 people. The company has 185.79 M outstanding shares of which 9.31 M shares are currently shorted by private and institutional investors with about 7.89 trading days to cover. More on Cerus
Moving together with Cerus Stock
Moving against Cerus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cerus Stock Highlights
| CEO and President and Director | William Greenman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCerus can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cerus' financial leverage. It provides some insight into what part of Cerus' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cerus (CERS) is traded on NASDAQ Exchange in USA. It is located in 1220 Concord Avenue, Concord, CA, United States, 94520 and employs 614 people. Cerus is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 258.25 M. Cerus conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 185.79 M outstanding shares of which 9.31 M shares are currently shorted by private and institutional investors with about 7.89 trading days to cover.
Cerus currently holds about 107.05 M in cash with 11.36 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check Cerus Probability Of Bankruptcy
Ownership AllocationCerus holds a total of 185.79 Million outstanding shares. The majority of Cerus outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cerus to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cerus. Please pay attention to any change in the institutional holdings of Cerus as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cerus Ownership Details
Cerus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-12-31 | 3.4 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 3.4 M | |
| Millennium Management Llc | 2024-12-31 | 2.9 M | |
| Ieq Capital, Llc | 2024-12-31 | 2.2 M | |
| Ing Investment Management Llc | 2024-12-31 | 1.8 M | |
| Citadel Advisors Llc | 2024-12-31 | 1.7 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.7 M | |
| Northern Trust Corp | 2024-12-31 | 1.6 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 1.6 M | |
| Ark Investment Management Llc | 2024-12-31 | 20.8 M | |
| Baker Bros Advisors Lp | 2024-12-31 | 19.5 M |
Cerus Historical Income Statement
Cerus Stock Against Markets
Cerus Corporate Management
| Carol Moore | Sr. VP of Regulatory Affairs, Quality and Clinical | Profile | |
| Matthew Notarianni | Director Relations | Profile | |
| Richard Benjamin | Chief Medical Officer | Profile | |
| Vivek Jayaraman | Chief Commercial Officer | Profile |
Additional Tools for Cerus Stock Analysis
When running Cerus' price analysis, check to measure Cerus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerus is operating at the current time. Most of Cerus' value examination focuses on studying past and present price action to predict the probability of Cerus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerus' price. Additionally, you may evaluate how the addition of Cerus to your portfolios can decrease your overall portfolio volatility.